FinVector is a Finnish cGMP manufacturer of viral-based gene therapy products with over 30 years of experience in drug discovery science and manufacturing. Its new 25,000 square meter Finport facility in Kuopio, opened in partnership with Ferring Pharmaceuticals, represents one of the world's largest viral vector manufacturing capacities using the iCELLis platform from Pall Corporation.
Viral vector manufacturing, gene therapy cGMP production, adenoviral vectors, drug substance and drug product manufacturing
1 site worldwide
No certifications on file yet.
No reviews available yet.
No documents available.